NovoCure (NVCR) shares were down over 3% in recent Friday trading after Wells Fargo downgraded the stock to equal-weight from overweight and slashed its price target to $14.50 from $40.
Separately, Wedbush also cut its price target to $18 from $27.
Trading volume stood at over 2.8 million shares against a daily average of around 1.3 million.
Price: 12.11, Change: -0.43, Percent Change: -3.42
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。